Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
VC Firms Commit More Than $1.9bn To Future Investments
Executive Summary
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
You may also be interested in...
J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple
After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
Third Rock Thinks Its Model Reassures Investors In Difficult Times
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.